http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0821301-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18258b0f0aeb7478e1258cb440bb4b83 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34 |
| filingDate | 2008-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99b70e163cd81a3f74d3741049b03ba1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cfd7cecfc11a9924bb908d0e86dabdc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3379d7e2215f050438b9bc9bce620d04 |
| publicationDate | 2019-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0821301-B1 |
| titleOfInvention | ISOSORBIDE ASPIRINATE COMPOUND, PHARMACEUTICAL COMPOSITION, AND THEIR USE |
| abstract | isosorbide aspirinate compound, pharmaceutical composition, and its use aspirin is one of the most widely used drugs in the treatment of inflammation, pain and fever. More recently, it has found application in the prevention of heart attack and stroke and is being studied as a chemopreventive agent for cancer. Despite its value, aspirin is still underused because it causes gastric bleeding. Technology under development potentially removes this problem. This is intended to reduce contact between the drug and the intestinal lining. a prodrug isosorbide aspirinate compound is thus provided. The compound has the general structure as shown in formula (i) wherein y is a C1 -C8 alkyl ester, a C1 -C8 alkoxy ester, a C3 -C10 cycloalkyl ester, an aryl ester, an alkylaryl ester cl-c8 or a -c (o) oranel, wherein ranel is a 5-membered or non-aromatic 5-membered ring having at least one carbon-substituted heteroatom in the ring system, which may be unsubstituted or substituted with at least one nitric oxide release group. |
| priorityDate | 2007-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 251.